Physician profile
Aurelia Anne Smith
NPI 1316277098
$1,034.39
in general payments reported to CMS, 2019-2025
18 companies · $36.34 in 2025
The $36.34 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $66.13 · 2022: $648 · 2023: $17.80 · 2024: $266 · 2025: $36.34.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $210 · Food and Beverage: $110.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $210.32 |
| Food and Beverage | $109.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $452.01 | 2022-2024 | Ultomiris, Soliris |
| Biogen, INC. | $99.67 | 2022-2025 | Vumerity |
| Sanofi-Aventis U.S. LLC | $66.13 | 2021 | |
| Lilly USA, LLC | $55.23 | 2022 | |
| Abbvie INC. | $53.27 | 2022-2023 | Qulipta |
| Celgene Corporation | $39.83 | 2022 | |
| Vanda Pharmaceuticals INC. | $35.87 | 2024 | Ponvory |
| Teva Pharmaceuticals USA, INC. | $34.48 | 2022 | |
| Amgen INC. | $33.83 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $26.26 | 2022 | |
| Neurocrine Biosciences, INC. | $21.35 | 2022 | |
| Novartis Pharmaceuticals Corporation | $19.50 | 2024 | |
| Amneal Pharmaceuticals LLC | $19.16 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.66 | 2025 | Wainua |
| Kyowa Kirin, INC. | $18.59 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $15.27 | 2022 | |
| Neurelis, INC. | $12.87 | 2022 | |
| Lundbeck LLC | $12.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aurelia Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.